Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner
Stocks in this Quantisnow insightHealth Care
Quantisnow market dataNASDAQ
HUMA
Humacyte Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2020
Get push alerts for HUMA
Full HUMA profile on Quantisnow Follow HUMA and get a push notification the moment its next story breaks.